Sub-unit vaccine against S. aureus-mediated infections: Set-up of nano-sized polymeric adjuvant

International Journal of Pharmaceutics

Volumn 452, Issue 1-2, 2013, Pages 390-401

  Colonna, C ^a   Dorati, R ^a   Conti, B ^a   Caliceti, P ^b   Genta, I ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

In vitro characterization; Nano sized adjuvant; Polymeric nanoparticles; S. aureus mediated infections; Sub unit vaccine

Indexed keywords

CRYOPROTECTIVE AGENT; IMMUNOLOGICAL ADJUVANT; POLYGLACTIN; RECOMBINANT COLLAGEN BINDING BACTERIAL ADHESIN FRAGMENT CNA19; STAPHYLOCOCCUS VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN STRUCTURE; ARTICLE; CYTOTOXICITY; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; SUSTAINED DRUG RELEASE; VACCINATION;

EID: 84884208375     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.05.037     Document Type: Article

References (45)

1. Akagi, T., Baba, M., Akashi, M., 2012. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine. Adv. Polym. Sci. 247, 31-64.
2. Bilati, U., Allemann, E., Doelker, E., 2005. Strategic approaches for overcome peptide and protein instability within biodegradable nano- and microparticles. Eur. J. Pharm. Biopharm. 59, 375-388. (Pubitemid 40342512)
3. British Pharmacopoeia, 2012. Buffer Solutions, Appendix I D.
4. Brown, E.L., Dumitrescu, O., Thomas, D., Badiou, C., Koers, E.M., Choudhury, P., Vazquez, V., Etienne, J., Lina, G., Vandenesch, F., Bowden, M.G., 2009. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect. 15, 156-164.
5. Bubeck Wardenburg, J., Palazzolo-Balance, A.M., Otto, M., Schneewind, O., DeLeo, F.R., 2008. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J. Infect. Dis. 198, 1166-1170.
6. Cheng, A.G., Kim, H.M., Burts, M.L., Krausz, L., Schneewind, O., Missiakas, D.M., 2009. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J. 23, 3393-4340.
7. Colonna, C., Conti, B., Perugini, P., Pavanetto, F., Modena, T., Dorati, R., Genta, I., 2007. Chitosan glutamate nanoparticles for protein delivery: development and effect on prolidase stability. J. Microencapsulation 24, 553-564. (Pubitemid 47180538)
8. Colonna, C., Dorati, R., Conti, B., Modena, T., Saino, E., Visai, L., Caliceti, P., Genta, I., 2009. Design and in vitro characterization of CNA loaded PLGA nanoparticles as subunit vaccine against S. aureus-mediated infections. In: AAPS Annual Meeting and Exposition, Los Angeles, (CA), USA, November 8-12.
9. Correia-Pinto, J.F., Csaba, N., Alonso, M.J., 2013. Vaccine delivery carriers: insights and future perspectives. Int. J. Pharm. 440, 27-38.
10. Costantino, L., Gandol., F., Tosi, G., Rivasi, F., Vandelli, M.A., Forni, F., 2005. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain-barrier. J. Control. Release 108, 84-96. (Pubitemid 41476677)
11. Cun, D., Jensen, D.K., Maltesen, M.J., Bunker, M., Whiteside, P., Scurr, D., Foged, C., Nielsen, H.M., 2011. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. Eur. J. Pharm. Biopharm. 77, 26-35.
12. De Gregorio, E., D'Oro, U., Wack, A., 2009. Immunology of TLR-independent vaccine adjuvants. Curr. Opin. Immunol. 21, 339-345.
13. Demana, P.H., Davies, M., Hook, S., Rades, T., 2005. Quil A-lipid powder formulations releasing ISCOMs and related colloidal structures upon hydration. J. Control. Release 103, 45-59. (Pubitemid 40248560)
14. Di Marco, M., Shamsuddin, S., Razak, K.A., Aziz, A.A., Devaux, C., Borghi, E., Levy, L., Sadun, C., 2010. Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation. Int. J. Nanomed. 5, 37-49.
15. Diep, B.A., Gill, S.R., Chang, R.F., Phan, T.H., Chen, J.H., Davidson, M.G., Lin, F., Lin, J., Carleton, H.A., Mongodin, E.F., Sensabaugh, G.F., Perdreau-Remington, F., 2006. Complete genome sequence of USA300, an epidemic clone of community-aquired methicillin resitant S. aureus. Lancet 367, 731-739. (Pubitemid 43326291)
16. Fattom, A.L., Horwith, G., Fuller, S., Propst, M., Naso, R., 2004. Development of Staph-VAX, a polysaccharide conjugate vaccine against S. aureus infections: from the lab bench to phase III clinical trials. Vaccine 22, 880-887. (Pubitemid 38177389)
17. Greef, R., Minamitake, Y., Peracchia, M.T., Trubetskoy, V., Torchilin, V., Langer, R.,\ 1994. Biodegradable long - circulating polymeric nanospheres. Science 263, 1600-1603. (Pubitemid 24128361)
18. Harper, D.M., 2009. Currently approved prophylactic HPV vaccines. Expert Rev. Vaccines 8, 1663-1679.
19. Joshi, D.P., Lan-Chun-Fung, Y.L., Pritchard, J.W., 1979. Determination of poly(vinyl alcohol) via its complex with boric acid and iodine. Anal. Chim. Acta 104, 153-160.
20. Look, M., Bandyopadhyay, A., Blum, J.S., Fahmy, T.M., 2010. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv. Drug. Deliv. Rev. 62, 378-393.
21. Lowy, F.D., 1998. Staphylococcus aureus infections. N. Engl. J. Med. 333, 520-532.
22. Moran, G.J., Krishnadasan, A., Gorwitz, R.J., Fosheim, G.E., McDougal, L.K., Carey, R.B., Talan, D.A., 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355, 666-674.
23. Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63. (Pubitemid 14203433)
24. Mundargi, R.C., Babu, V.R., Rangaswamy, V., Patel, P., Aminabhavi, T.M., 2008. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J. Control. Release 125, 193-209.
25. Nanra, J.S., Timofeyeva, Y., Buitrago, S.M., Sellman, B.R., Dilts, D.A., Fink, P., Nunez, L., Hagen, M., Matsuka, Y.V., Mininni, T., Zhu, D., Pavliak, V., Green, B.A., Jansen, K.U., Anderson, A.S., 2009. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus. Implications for vaccine design. Vaccine 27, 3276-3280.
26. Nathwani, D., 2009. Health economic issues in the treatment of drug-resistant serious Gram-positive infections. J. Infect. 59, 40-50.
27. Ogawa, Y., Okada, H., Heya, T., Shimamoto, T., 1989. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules - serum drug level profiles and pharmacological effects in animals. J. Pharm. Pharmacol. 41, 439-444. (Pubitemid 19189583)
28. O'Hagan, D.T., Rappuoli, R., De Gregorio, E., Tsai, T., Del Giudice, G., 2011. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines 10, 447-462.
29. Okada, H., 1997. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv. Drug. Deliv. Rev. 28, 43-70. (Pubitemid 27497673)
30. Olesen, O.F., Lonnroth, A., Mulligan, B., 2009. Human vaccine research in the European Union. Vaccine 27, 640-645.
31. Otto, M., 2008. Targeted immunotherapy for staphylococcal infections. BioDrugs 22, 27-36.
32. Oyewumi, M.O., Kumar, A., Cui, Z., 2010. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 9, 1095-1107.
33. Owens, D.E., Peppas, N.A., 2006. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102. (Pubitemid 41773257)
34. Patti, M.J., Jonsson, H., Guss, B., Switalski, L.M., Wiberg, K., Lindberg, M., Hook, M., 1998. Molecular characterization and expression of a gene encoding a Staphylococcus aureus collagen adhesin. J. Biol. Chem. 267, 4766-4772.
35. Peek, L.J., Middaugh, C.R., Berkland, C., 2008. Nanotechnology in vaccine delivery. Adv. Drug. Deliv. Rev. 60, 915-928.
36. Perrie, Y., Kirby, D.J., Bramwell, V.W., Mohammed, A.R., 2007. Recent developments in particulate vaccines. Recent Pat. Drug Deliv. Formul. 1, 117-129.
37. Pistel, K.F., Kissel, T., 2000. Effects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique. J. Microencapsulation 17, 467-483. (Pubitemid 30420829)
38. Projan, S.J., Nesin, M., Dunman, P.M., 2006. Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr. Opin. Pharmacol. 6, 473-479. (Pubitemid 44362069)
39. Rivas, J.M., Speziale, P., Patti, J.M., Hook, M., 2004. MSCRAMM - targeted vaccines and immunotherapy for staphylococcal infection. Curr. Opin. Drug Discov. Develop. 7, 223-227. (Pubitemid 44111954)
40. Storni, T., Kundig, T.M., Senti, G., Johansen, P., 2005. Immunity in response to particulate antigen-delivery systems. Adv. Drug. Deliv. Rev. 57, 333-335.
41. Stranger-Jones, Y.K., Bae, T., Schneewind, O., 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U.S.A. 103, 16942-16947. (Pubitemid 44737357)
42. Tamber, H., Johansen, P., Merkle, H.P., Gander, B., 2005. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug. Deliv. Rev. 57, 357-376. (Pubitemid 39555502)
43. Tushscherr, L.P., Buzzzola, F.R., Alvarrez, L.P., Lee, J.C., Sordelli, D.O., 2008. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect. Immun. 78, 5738-5744.
44. Vangala, A., Kirby, D., Rosenkrands, I., Agger, E.M., Andersen, P., Perrie, Y., 2006. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J. Pharm. Pharmacol. 58, 787-799. (Pubitemid 43836165)
45. Vila, A., Sanchez, A., Tobio, M., Calvo, P., Alonso, M.J., 2002. Design of biodegradable particles for protein delivery. J Control. Release 1-2, 15-24. (Pubitemid 34081849)